2025 Q4 -tulosraportti
Vain PDF
33 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
15 t sitten15 t sittenDoes anyone know why this one is so volatile with big movements up and down lately?
·12 t sittenPurchased analyses and studies that do not meet hyped expectations are a major cause. The high market capitalization does not make things better. It will surely calm down if the price finds the right level. Probably a lower level. The positive thing is that they are still on track, unlike much other biotech. Long-term, 3-4 years, there is a chance for a return to a higher level.
20 t sitten20 t sittenThis is exactly what I was talking about with the upcoming results. Safety and tolerability results are almost redundant, whether from CU/EAP or P2b when there’s little to no efficacy data. CS01 is based on a substance that has a historically decorated safety profile in other indications and it’s safety has been widely researched in P1 and P2a. I hate to say it, but results like these are next to meaningless towards a BP deal, yet people claimed this would be a great trigger. Even if we do get efficacy data later, it will come from a dataset of 6 patients. It is such a small subset I wonder if it’ll make a difference if it’s positive. We’ll have t see I guess. Stifel starting coverage and setting a buy rating with a target price of 20SEK was good news, but it’s not enough to hold this boat afloat and neither is almost redundant test results.
16 t sitten16 t sitten"results like these are next to meaningless towards a BP deal, yet people claimed this would be a great trigger" I think you got it wrong: 1. Safety & tolerability may not mean anything to the day-traders and speculators but it's #1 requirement for BP to continue studies and possible cooperation. 2. I think most people meant that the efficacy data is the great trigger, which will be communicated in Q2, as planned.13 t sitten13 t sittenRespectfully, I don’t think I got it wrong. I stand firmly behind the statement that the compound that CS01 is based on has a decorated safety profile in other indications. We have had in vitro trials assessing the theoretical side of safety and tolerability of the compound for this specific indication as well as two in vivo clinical trials (P1 and P2a) where the primary endpoints were safety and tolerability. Not to even mention what we got now in the latest readout. I personally think that all this combined is a significant enough amount of data to conclude with relative certainty that the compound is going to be safe for the majority of patients living with this condition. On the contrary what we have almost no clinical evidence of is efficacy. Efficacy has been a secondary and rather miniscule endpoint in the studies so far, including the upcoming P2b study, which is yet again primarily endpointed towards safety and tolerability. With the recently published knowledge of dropouts from the already limited CU/EAP, I am questioning if the Q2 efficacy data will provide any meaningful or concludent evidence towards a BP deal. In conclusion, I think it stands to reason that the risk of CS01 failing clinical studies and not making it to market due to safety concerns is neglible, while the efficacy concerns remain significant and yet to be proven wrong.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
33 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 15 t sitten15 t sittenDoes anyone know why this one is so volatile with big movements up and down lately?·12 t sittenPurchased analyses and studies that do not meet hyped expectations are a major cause. The high market capitalization does not make things better. It will surely calm down if the price finds the right level. Probably a lower level. The positive thing is that they are still on track, unlike much other biotech. Long-term, 3-4 years, there is a chance for a return to a higher level.
- 20 t sitten20 t sittenThis is exactly what I was talking about with the upcoming results. Safety and tolerability results are almost redundant, whether from CU/EAP or P2b when there’s little to no efficacy data. CS01 is based on a substance that has a historically decorated safety profile in other indications and it’s safety has been widely researched in P1 and P2a. I hate to say it, but results like these are next to meaningless towards a BP deal, yet people claimed this would be a great trigger. Even if we do get efficacy data later, it will come from a dataset of 6 patients. It is such a small subset I wonder if it’ll make a difference if it’s positive. We’ll have t see I guess. Stifel starting coverage and setting a buy rating with a target price of 20SEK was good news, but it’s not enough to hold this boat afloat and neither is almost redundant test results.16 t sitten16 t sitten"results like these are next to meaningless towards a BP deal, yet people claimed this would be a great trigger" I think you got it wrong: 1. Safety & tolerability may not mean anything to the day-traders and speculators but it's #1 requirement for BP to continue studies and possible cooperation. 2. I think most people meant that the efficacy data is the great trigger, which will be communicated in Q2, as planned.13 t sitten13 t sittenRespectfully, I don’t think I got it wrong. I stand firmly behind the statement that the compound that CS01 is based on has a decorated safety profile in other indications. We have had in vitro trials assessing the theoretical side of safety and tolerability of the compound for this specific indication as well as two in vivo clinical trials (P1 and P2a) where the primary endpoints were safety and tolerability. Not to even mention what we got now in the latest readout. I personally think that all this combined is a significant enough amount of data to conclude with relative certainty that the compound is going to be safe for the majority of patients living with this condition. On the contrary what we have almost no clinical evidence of is efficacy. Efficacy has been a secondary and rather miniscule endpoint in the studies so far, including the upcoming P2b study, which is yet again primarily endpointed towards safety and tolerability. With the recently published knowledge of dropouts from the already limited CU/EAP, I am questioning if the Q2 efficacy data will provide any meaningful or concludent evidence towards a BP deal. In conclusion, I think it stands to reason that the risk of CS01 failing clinical studies and not making it to market due to safety concerns is neglible, while the efficacy concerns remain significant and yet to be proven wrong.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
33 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 15 t sitten15 t sittenDoes anyone know why this one is so volatile with big movements up and down lately?·12 t sittenPurchased analyses and studies that do not meet hyped expectations are a major cause. The high market capitalization does not make things better. It will surely calm down if the price finds the right level. Probably a lower level. The positive thing is that they are still on track, unlike much other biotech. Long-term, 3-4 years, there is a chance for a return to a higher level.
- 20 t sitten20 t sittenThis is exactly what I was talking about with the upcoming results. Safety and tolerability results are almost redundant, whether from CU/EAP or P2b when there’s little to no efficacy data. CS01 is based on a substance that has a historically decorated safety profile in other indications and it’s safety has been widely researched in P1 and P2a. I hate to say it, but results like these are next to meaningless towards a BP deal, yet people claimed this would be a great trigger. Even if we do get efficacy data later, it will come from a dataset of 6 patients. It is such a small subset I wonder if it’ll make a difference if it’s positive. We’ll have t see I guess. Stifel starting coverage and setting a buy rating with a target price of 20SEK was good news, but it’s not enough to hold this boat afloat and neither is almost redundant test results.16 t sitten16 t sitten"results like these are next to meaningless towards a BP deal, yet people claimed this would be a great trigger" I think you got it wrong: 1. Safety & tolerability may not mean anything to the day-traders and speculators but it's #1 requirement for BP to continue studies and possible cooperation. 2. I think most people meant that the efficacy data is the great trigger, which will be communicated in Q2, as planned.13 t sitten13 t sittenRespectfully, I don’t think I got it wrong. I stand firmly behind the statement that the compound that CS01 is based on has a decorated safety profile in other indications. We have had in vitro trials assessing the theoretical side of safety and tolerability of the compound for this specific indication as well as two in vivo clinical trials (P1 and P2a) where the primary endpoints were safety and tolerability. Not to even mention what we got now in the latest readout. I personally think that all this combined is a significant enough amount of data to conclude with relative certainty that the compound is going to be safe for the majority of patients living with this condition. On the contrary what we have almost no clinical evidence of is efficacy. Efficacy has been a secondary and rather miniscule endpoint in the studies so far, including the upcoming P2b study, which is yet again primarily endpointed towards safety and tolerability. With the recently published knowledge of dropouts from the already limited CU/EAP, I am questioning if the Q2 efficacy data will provide any meaningful or concludent evidence towards a BP deal. In conclusion, I think it stands to reason that the risk of CS01 failing clinical studies and not making it to market due to safety concerns is neglible, while the efficacy concerns remain significant and yet to be proven wrong.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt